Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Label indication Loteprednol etabonate ophthalmic suspension is indicated for the treatment of steroid-responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea and anterior segment of the globe such as allergic conjunctivitis, acne rosacea, superficial punctate keratitis, herpes zoster keratitis, iritis, cyclitis, selected infective conjunctivitides, when the inherent hazard of steroid use is accepted to… FDA label
Also known as Loteprednol etabonate suspension, Loteprednol etabonate 0.2%, Loteprednol Etabonate Ophthalmic Gel dosed TID, Loteprednol Etabonate dosed, Loteprednol Etabonate Gel (BID), LE
Loteprednol Etabonate · 9 trials · 6 indications
Slit lamp examination was performed. White blood cell accumulation in anterior aqueous humor was assessed by the Investigator during slit lamp examination and graded on a 5-point scale: Grade 0 = no cells seen; Grade 1 = 1 to 5 cells; Grade 2 = 6 to 15 cells; Grade 3 = 16 to 30 cells; Grade 4 = \> 30 cells. Complete resolution of AC cells was defined as Cell score = 0 in the study eye.
Ocular pain, defined as a positive sensation of the eye, including foreign body sensation, stabbing, throbbing, or aching, was assessed and graded by subjects on a 6-point scale: 0 (None), 1 (Minimal), 2 (Mild), 3 (Moderate), 4 (Moderately Severe), and 5 (Severe). Complete Resolution of Ocular Pain was defined as Pain Score = 0.
White blood cell accumulation in anterior aqueous humor was assessed by the Investigator during slit lamp examination and graded on a 5-point scale: Grade 0 = no cells seen; Grade 1 = 1 to 5 cells; Grade 2 = 6 to 15 cells; Grade 3 = 16 to 30 cells; Grade 4 = \> 30 cells. Lower score indicated better outcome. Complete resolution of AC cells was defined as cell score = 0 in the study eye.
Ocular pain, defined as a positive sensation of the eye, including foreign body sensation, stabbing, throbbing, or aching, was assessed and graded by subjects on the 6-point scale, with 0=None and 5=Severe.
Anterior Chamber Inflammation (for subjects that could only be examined with a pen light and a 20D \[g20 Diopter\] magnifying lens): 0 = None Clear anterior chamber with no visible clouding (Tyndall effect and cells combined). Red reflex normal 1. = Mild Mild anterior chamber clouding. Clear iris pattern on visualization. Red reflex normal 2. = Moderate Moderate anterior chamber clouding 3. = Severe Severe anterior chamber clouding. Iris pattern not clearly visualized. Red reflex diminished 4. = Very severe Severe anterior chamber clouding with a white and/or milky appearance of the anterior chamber. Red reflex absent or severely diminished
Bulbar conjunctival injection (sign) evaluated using a grading scale from 0-3: where 0 = Absent and 3 = Severe
Ocular itching (symptom) evaluated using a grading scale from 0-4 where 0 = Absent and 4 = Severe
Participants with complete resolution of anterior chamber cells(ACC). Cells were graded on a 0-4 scale, where 0=no cells and 4=\>30 cells
Participants with no pain, graded on a 0-5 scale, 0=no pain and 5=severe pain
Number of Study eyes with complete resolution(Grade 0) of anterior chamber cells (ACC) for loteprednol and vehicle. Accumulation of white cells in aqueous graded on a scale of 0-4 where grade 0=no cells. Investigators assessed ACC using a slit lamp.
A combination of the grades for inflammatory cells and flare in the anterior chamber. Cells: accumulation of white blood cells in aqueous. 0=No cells seen; 1=1-5 cells; 2=6-15 cells; 3=16-30 cells; 4= \>30 cells. Flare: Scattering of a slit lamp light beam when directed into the anterior chamber (Tyndall effect). 0=None; 1=Mild; 2=Moderate; 3=Severe; 4=Very severe.
Pain: A positive sensation of the eye, including foreign body sensation, stabbing, throbbing, or aching. Grade 0 = None; 1=Minimal; 2=Mild; 3=Moderate; 4=Moderately Severe; 5=Severe
| Arm | Type | Description |
|---|---|---|
| Loteprednol Etabonate Ophthalmic Gel dosed TID | EXPERIMENTAL | Gel |
| Loteprednol Etabonate Ophthalmic Gel dosed BID | EXPERIMENTAL | Gel |
| Vehicle Gel | PLACEBO_COMPARATOR | Vehicle |
| Loteprednol Etabonate Gel (BID) | EXPERIMENTAL | Loteprednol Etabonate Gel 0.38% administered two times daily (BID) |
| Vehicle Gel (BID) | PLACEBO_COMPARATOR | Vehicle gel administered two times daily (BID) |
| Vehicle (BID) | ACTIVE_COMPARATOR | Vehicle of Loteprednol Etabonate Gel 0.38% administered two times daily (BID). |
| Loteprednol Etabonate Gel (TID) | EXPERIMENTAL | Loteprednol Gel 0.38% administered three times daily (TID). |
| Vehicle (TID) | ACTIVE_COMPARATOR | Vehicle of Loteprednol Etabonate Gel 0.38% administered three times daily (TID). |
| Loteprednol etabonate | EXPERIMENTAL | Loteprednol etabonate 0.5% |
| Prednisolones acetate | ACTIVE_COMPARATOR | Prednisolone acetate 1.0% |
| Alrex | EXPERIMENTAL | Ophthalmic formulation containing the active ingredient loteprednol etabonate, 0.2% |
| Patanol | ACTIVE_COMPARATOR | Ophthalmic solution containing olopatadine, 0.1% |
| Vehicle | PLACEBO_COMPARATOR | Vehicle of loteprednol etabonate ophthalmic suspension |
| Loteprednol Etabonate TID | EXPERIMENTAL | loteprednol etabonate ophthalmic suspension, 0.5%, TID |
| Loteprednol Etabonate QID | EXPERIMENTAL | loteprednol etabonate ophthalmic suspension, 0.5%, QID |
| Name | Type | Description |
|---|---|---|
| Loteprednol Etabonate Ophthalmic Gel dosed TID | DRUG | Gel |
| Loteprednol Etabonate Ophthalmic Gel dosed BID | DRUG | Gel |
| Vehicle Gel | DRUG | Gel |
| Loteprednol Etabonate Gel (BID) | DRUG | One drop of LE gel instilled into the study eye two times per day (BID) for 14 days |
| Vehicle Gel (BID) | DRUG | One drop of vehicle gel instilled into the study eye two times per day (BID) for 14 days |
| Loteprednol Etabonate Gel (TID) | DRUG | One drop of LE gel instilled into the study eye three times per day (TID) for 14 days. |
| Vehicle (BID) | DRUG | One drop of vehicle instilled into the study eye two times per day (BID) for 14 days |
| Vehicle (TID) | DRUG | One drop of vehicle instilled into the study eye three times per day (TID) for 14 days |
| Loteprednol etabonate | DRUG | 1-2 Ophthalmic drops administered to study eye four times daily (QID) for 14 days post surgery. Tapered to twice daily (BID) for 7 days. Then once daily (QD) for 7 days. |
| Prednisolones acetate | DRUG | 1-2 Ophthalmic drops administered to study eye four times daily (QID) for 14 days post surgery. Tapered to twice daily (BID) for 7 days. Then once daily (QD) for 7 days. |
| Loteprednol etabonate 0.2% | DRUG | 1 drop of Alrex 4 times daily (QID) in both eyes at approximately 4 hour intervals for 2 weeks. |
| Olopatadine 0.1% | DRUG | 1 drop of Patanol 2 times daily (BID)at intervals of 6-8 hours or more for 2 weeks. |
| Vehicle of Loteprednol Etabonate | DRUG | Topical administration of vehicle of loteprednol etabonate ophthalmic suspension 1-2 drops in study eye QID, postoperative day 1-14. |
| Vehicle of Ophthalmic Loteprednol Etabonate | DRUG | Vehicle of ophthalmic loteprednol etabonate administered postoperatively to study eye 4 times a day(QID) for 14 days. |
| loteprednol etabonate ophthalmic suspension, 0.5% | DRUG | TID |
Key Inclusion Criteria: 1. Be 18 years or older on the date the Informed Consent Form (ICF) is signed and with the capacity to provide voluntary informed consent. 2. Be able to read, understand, and provide written informed consent on the Institutional Review Board (IRB)/Ethics Committee (EC) appro...
Loteprednol etabonate is an ophthalmic corticosteroid developed for inflammatory eye conditions. Its studied indications include ocular inflammation and pain following cataract surgery, dry eye, and seasonal allergic conjunctivitis. It is being developed by Bausch + Lomb Corporation under the ticker BLCO and is currently in Phase 3 clinical development.
Loteprednol etabonate is developed by Bausch + Lomb Corporation, which trades under the ticker BLCO. The company has sponsored four Phase 3 clinical trials of the drug, all of which have been completed, enrolling a total of 1,653 participants across the studies.
Loteprednol etabonate is in Phase 3 clinical development. Four Phase 3 trials have been completed, and no trials are currently active. The studies were randomized, double-blind, and placebo-controlled, and they enrolled a combined total of 1,653 participants.
Four completed Phase 3 trials have evaluated loteprednol etabonate: NCT02786901, NCT02208297, NCT01996839, and NCT01475643. The first three studied ocular inflammation and pain following cataract surgery in adults, while NCT01475643 compared loteprednol with prednisolone for intraocular inflammation after cataract surgery in children.
Yes. Loteprednol etabonate is also known as loteprednol etabonate ophthalmic suspension, loteprednol etabonate suspension, loteprednol etabonate 0.5%, loteprednol etabonate 0.2%, and loteprednol etabonate ophthalmic gel. These names refer to the same active drug in different ophthalmic formulations and dosing regimens.